<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel rdf:about="https://hdl.handle.net/20.500.11811/796">
<title>Klinik und Poliklinik für Orthopädie und Unfallchirurgie</title>
<link>https://hdl.handle.net/20.500.11811/796</link>
<description/>
<items>
<rdf:Seq>
<rdf:li rdf:resource="https://hdl.handle.net/20.500.11811/13789"/>
<rdf:li rdf:resource="https://hdl.handle.net/20.500.11811/13787"/>
<rdf:li rdf:resource="https://hdl.handle.net/20.500.11811/13785"/>
<rdf:li rdf:resource="https://hdl.handle.net/20.500.11811/13595"/>
</rdf:Seq>
</items>
<dc:date>2026-04-10T21:47:23Z</dc:date>
</channel>
<item rdf:about="https://hdl.handle.net/20.500.11811/13789">
<title>Microbiological Profiles of Patients with Acute Periprosthetic Joint Infection Undergoing Debridement, Antibiotics, Irrigation and Implant Retention (DAIR)</title>
<link>https://hdl.handle.net/20.500.11811/13789</link>
<description>Microbiological Profiles of Patients with Acute Periprosthetic Joint Infection Undergoing Debridement, Antibiotics, Irrigation and Implant Retention (DAIR)
Zellner, Alberto Alfieri; Watzlawik, Niclas; Roos, Jonas; Hischebeth, Gunnar Thorben Rembert; Molitor, Ernst; Franz, Alexander; Fröschen, Frank Sebastian
&lt;strong&gt;Background:&lt;/strong&gt; Periprosthetic joint infection (PJI) is one of the most serious complications following total joint arthroplasty. The debridement, antibiotics, irrigation, and implant retention (DAIR) procedure is commonly employed to treat acute, early-stage infections, but its success is highly variable, influenced by factors such as pathogen virulence and antibiotic susceptibility profiles. This study aimed to evaluate the impact of pathogens responsible for these infections on the outcome of DAIR. &lt;strong&gt;Methods:&lt;/strong&gt; This retrospective, single-center study analyzed the microbiological profiles of 116 patients (66 hips and 50 knees) treated for acute periprosthetic joint infections (PJIs) with DAIR between 2018 and 2022. Acute PJI was defined as a duration of symptom less than three weeks, according to the criteria established by the Tsukayama and Izakovicova classification. Preoperative joint aspirations, intraoperatively collected tissue samples, and sonication of the exchanged mobile parts were analyzed for each case. We differentiated between monomicrobial PJI, polymicrobial PJI (defined as the identification of more than one microorganism from preoperative joint fluid aspiration or intraoperative samples), and difficult-to-treat (DTT) pathogens. &lt;strong&gt;Results:&lt;/strong&gt; In this cohort, the following pathogen profiles were identified: culturenegative cases accounted for 11.1% of infections, while 64.2% were attributed to Grampositive bacteria, 19.8% to Gram-negative bacteria, and 4.9% to fungal pathogens. Among the identified microorganisms, coagulase-negative staphylococci (CNS) were the most frequently detected, exhibiting a notable oxacillin resistance rate of 52.9% and rifampicin resistance rate of 28.7%. Additionally, no significant difference in revision-free implant survival was found between patients with DTT pathogens and/or polymicrobial PJI and those without such infections. &lt;strong&gt;Conclusions:&lt;/strong&gt; This study highlights that pathogens in prosthetic joint infections (PJIs) do not solely determine outcomes, as patient-specific factors (comorbidities, implant type) may also play a key role. Regional variations in pathogens and antibiotic resistance patterns should guide empirical therapy. For instance, this study found a high reliance on vancomycin due to high oxacillin resistance in CNS, the most frequent causative pathogen.
</description>
<dc:date>2025-08-30T00:00:00Z</dc:date>
</item>
<item rdf:about="https://hdl.handle.net/20.500.11811/13787">
<title>Passive Blood-Flow-Restriction Exercise's Impact on Muscle Atrophy Post-Total Knee Replacement</title>
<link>https://hdl.handle.net/20.500.11811/13787</link>
<description>Passive Blood-Flow-Restriction Exercise's Impact on Muscle Atrophy Post-Total Knee Replacement
Franz, Alexander; Heiß, Luisa; Schlotmann, Marie; Ji, Sanghyeon; Strauss, Andreas Christian; Randau, Thomas; Fröschen, Frank Sebastian
&lt;strong&gt;Background/Objectives:&lt;/strong&gt; Total knee arthroplasty (TKA) is commonly associated with postoperative muscle atrophy and weakness, while traditional rehabilitation is often limited by pain and patient compliance. Passive blood flow restriction (pBFR) training may offer a safe, low-threshold method to attenuate muscle loss in this early phase. This pilot study examined the feasibility, safety, and early effects of pBFR initiated during hospitalization on muscle mass, swelling, and functional recovery after TKA. &lt;strong&gt;Methods:&lt;/strong&gt; In a prospective, single-blinded trial, 26 patients undergoing primary or aseptic revision TKA were randomized to either a control group (CON: sham BFR at 20 mmHg) or intervention group (INT: pBFR at 80% limb occlusion pressure). Both groups received 50 min daily in-hospital rehabilitation sessions for five consecutive days. Outcomes, including lean muscle mass (DXA), thigh/knee circumference, 6 min walk test (6 MWT), handgrip strength, and patientreported outcomes, were assessed preoperatively and at discharge, six weeks, and three months postoperatively. Linear mixed models with Bonferroni correction were applied. &lt;strong&gt;Results:&lt;/strong&gt; The INT group showed significant preservation of thigh circumference (&lt;em&gt;p&lt;/em&gt; = 0.002), reduced knee swelling (&lt;em&gt;p&lt;/em&gt; &lt; 0.001), and maintenance of lean muscle mass (&lt;em&gt;p&lt;/em&gt; &lt; 0.01), compared with CON, which exhibited significant declines. Functional performance improved faster in INT (e.g., 6 MWT increase at T3: +23.7%, &lt;em&gt;p&lt;/em&gt; &lt; 0.001; CON: −7.2%, n.s.). Quality of life improved in both groups, with greater gains in INT (&lt;em&gt;p&lt;/em&gt; &lt; 0.05). No adverse events were reported. &lt;strong&gt;Conclusions:&lt;/strong&gt; Initiating pBFR training on the first postoperative day is feasible, safe, and effective in preserving muscle mass and reducing swelling after TKA. These findings extend prior BFR research by demonstrating its applicability in older, surgical populations. Further research is warranted to evaluate its integration with standard rehabilitation programs and long-term functional benefits.
</description>
<dc:date>2025-07-23T00:00:00Z</dc:date>
</item>
<item rdf:about="https://hdl.handle.net/20.500.11811/13785">
<title>In Vivo Antibiotic Elution and Inflammatory Response During Two-Stage Total Knee Arthroplasty Revision</title>
<link>https://hdl.handle.net/20.500.11811/13785</link>
<description>In Vivo Antibiotic Elution and Inflammatory Response During Two-Stage Total Knee Arthroplasty Revision
Behrens, Julika Johanna; Franz, Alexander; Schildberg, Frank Alexander; Rudowitz, Markus; Grote, Stefan; Fröschen, Frank Sebastian
&lt;strong&gt;Introduction: &lt;/strong&gt;Two-stage revision with an antibiotic-loaded, temporary static cement spacer is a common treatment for periprosthetic joint infection (PJI) of the knee. However, limited data exists on in vivo antibiotic elution kinetics after spacer implantation. This pilot study uses the technique of microdialysis (MD) to collect intra-articular knee samples. The aim was to evaluate MD as an intra-articular sampling method to detect spacer-eluted antibiotics within 72 h after surgery and to determine whether they show specific elution kinetics. &lt;br/&gt; &#13;
&#13;
&lt;strong&gt;Methods:&lt;/strong&gt; Ten patients (six male, four female; age median 71.5 years) undergoing two-stage revision for knee PJI were included. A MD catheter was inserted into the joint during explantation of the infected inlying implant and implantation of a custom-made static spacer coated with COPAL cement (0.5 g gentamicin (G) and 2 g vancomycin (V)). Over 72 h postoperatively, samples were collected and analyzed for spacer-eluted antibiotics, intravenously administered antibiotics (e.g., cefazolin and cefuroxime), metabolic markers (glucose and lactate), and Interleukin-6 (IL-6). Local and systemic levels were compared. &lt;br/&gt; &#13;
&#13;
&lt;strong&gt;Results:&lt;/strong&gt; All catheters were positioned successfully and well tolerated for 72 h. Antibiotic concentrations in MD samples peaked within the first 24 h (G: median 9.55 &amp;micro;g/mL ; V: 37.57 &amp;micro;g/mL [95% CI: 3.26–81.6]) and decreased significantly over 72 h (for both &lt;em&gt;p&lt;/em&gt; &lt; 0.05, G: 4.27 &amp;micro;g/mL [95% CI: 2.26–7.2]; V: 9.69 &amp;micro;g/mL [95% CI: 3.86–24]). MD concentrations consistently exceeded blood levels (&lt;em&gt;p&lt;/em&gt; &lt; 0.05), while intravenously administered antibiotics showed higher blood concentrations. Glucose in MD samples decreased from 17.71 mg/dL to 0.89 mg/dL (&lt;em&gt;p&lt;/em&gt; &lt; 0.05). IL-6 and lactate concentrations showed no difference between MD and blood samples. &lt;br/&gt; &#13;
&#13;
&lt;strong&gt;Conclusions:&lt;/strong&gt; Monitoring antibiotics eluted by a static spacer with intra-articular MD for 72 h is feasible. Gentamicin and vancomycin levels remained above the minimal inhibitory concentration. Differentiating infection from surgical response using metabolic and immunological markers remains challenging. Prolonged in vivo studies with MD are required to evaluate extended antibiotic release in two-stage exchanges.
</description>
<dc:date>2025-07-24T00:00:00Z</dc:date>
</item>
<item rdf:about="https://hdl.handle.net/20.500.11811/13595">
<title>The PJI-TNM Classification as Predictor for Revision-Free Implant Survival Rates in Patients with Periprosthetic Joint Infection of the Hip or Knee Joint</title>
<link>https://hdl.handle.net/20.500.11811/13595</link>
<description>The PJI-TNM Classification as Predictor for Revision-Free Implant Survival Rates in Patients with Periprosthetic Joint Infection of the Hip or Knee Joint
Fröschen, Frank Sebastian; Greber, Lisa; Molitor, Ernst; Hischebeth, Gunnar Thorben Rembert; Franz, Alexander; Randau, Thomas Martin
Background: Periprosthetic joint infections (PJIs) remain a major challenge in arthroplasty. This study tries to evaluate the PJI-TNM classification as predictor for the revision-free implant survival in patients with PJI of the hip or knee joint. Methods: To this end, we perform a retrospective study of all consecutive patients with PJI of an inlying hip or knee arthroplasty between January 2015 and December 2019. Results: A total of 443 cases (hip: &lt;em&gt;n&lt;/em&gt; = 247; knee &lt;em&gt;n&lt;/em&gt; = 196) were identified. In total, 439 patients underwent surgery (DAIR: &lt;em&gt;n&lt;/em&gt; = 138 cases (31%), explantation: &lt;em&gt;n&lt;/em&gt; = 272 (61%), irrigation with debridement without exchange of implant components: &lt;em&gt;n&lt;/em&gt; = 29 (6.5%)). Four patients refused surgical treatment and 39.5% were lost to follow-up. In total, 78 patients died during follow-up and 27 deaths were directly related to PJI/complications during treatment. Patients with inlying "standard"-implants (&lt;em&gt;p&lt;/em&gt; &lt; 0.001) and without previous history of PJI (&lt;em&gt;p&lt;/em&gt; = 0.002) displayed a significantly higher postoperative revision-free implant survival. In terms of the PJI-TNM subclassification, patients with loosened implants but without soft-tissue defects (T1) displayed the highest revision-free implant survival. In contrast, patients classified as M3 (no surgical treatment possible) displayed an inferior outcome compared to M0, M1, or M2. Patients with different N-subclassifications ("non-human cells"/causative pathogen) did not display differences in revision-free implant survival. Conclusions: The PJI-TNM classification is well suited to classify PJIs. Its complexity allows for more than 500 different combinations of classifications. Further validation data are needed, but to us, the PJI-TNM classification seems to offer the possibility of comparing patients with PJIs. It may, therefore, be a very valuable tool in order to compare cohorts with PJIs and provide individual data for patient specific outcomes.
</description>
<dc:date>2025-05-15T00:00:00Z</dc:date>
</item>
</rdf:RDF>
